Geron in Boehringer deal to detect telomerase:
This article was originally published in Clinica
Executive Summary
Geron and Boehringer Mannheim are collaborating worldwide to develop and commercialise research aimed at monitoring the enzyme telomerase, which is a measure of the presence and severity of cancers. Geron will receive funding and milestone payments, as well as royalties on eventual products. Boehringer will get exclusive rights outside the US on products, and will be responsible for pre-clinical and clinical trials. Both companies will co-promote any eventual products in the US. Telomerase is claimed to be the "universal" cancer marker, having been found where more than 20 different cancer types are present, but not detected in most normal tissue.